Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
BIO REFERENCE LABORATORIES INC (BRLI)
|
Add to portfolio |
|
|
|
| Price: |
$10.21
| | Metrics |
| OS: |
27.8
|
M
| |
15
|
% ROE
|
| Market cap: |
$284
|
M
| |
16
|
% ROIC
|
|
Net debt:
|
$44.7
|
M
| |
0.4
|
x Debt/EBITDA
|
|
EV:
|
$329
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$120
|
M
| |
2.7
|
x EV/EBITDA
|
|
EBIT
|
$89.5
|
M
| |
3.7
|
x EV/EBIT
|
| EPS |
$1.82
| |
5.6
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Oct-31-14 | Oct-31-13 | Oct-31-12 | Oct-31-11 | Oct-31-10 | Oct-31-09 | Oct-31-08 | Oct-31-07 |
| Revenues | 832.3 | 715.4 | 614.3 | 522.1 | 458.0 | 362.7 | 301.1 | 250.4 |
| Revenue growth | 16.3% | 16.5% | 17.7% | 14.0% | 26.3% | 20.5% | 20.2% | 29.7% |
| Cost of goods sold | 668.5 | 566.0 | 483.9 | 414.2 | 336.8 | 268.1 | 153.8 | 124.0 |
| Gross profit | 163.8 | 149.4 | 130.3 | 107.9 | 121.3 | 94.5 | 147.2 | 126.4 |
| Gross margin | 19.7% | 20.9% | 21.2% | 20.7% | 26.5% | 26.1% | 48.9% | 50.5% |
| General and administrative | 208.9 | 177.5 | 154.9 | 132.0 | 112.0 | 86.8 | 75.9 | 64.1 |
| EBITA | 85.3 | 83.0 | 76.7 | 61.1 | 49.7 | 38.3 | 28.6 | 25.1 |
| EBITA margin | 10.3% | 11.6% | 12.5% | 11.7% | 10.8% | 10.6% | 9.5% | 10.0% |
| Amortization of intangibles | 1.9 | 1.0 | 0.6 | 1.3 | 1.3 | | | |
| EBIT | 83.4 | 82.0 | 76.1 | 59.8 | 48.4 | 38.3 | 28.6 | 25.1 |
| EBIT margin | 10.0% | 11.5% | 12.4% | 11.4% | 10.6% | 10.6% | 9.5% | 10.0% |
| Pre-tax income | 81.0 | 81.1 | 74.5 | 64.8 | 47.0 | 38.6 | 26.7 | 22.9 |
| Income taxes | 34.2 | 35.3 | 32.4 | 28.5 | 20.6 | 16.7 | 11.1 | 9.0 |
| Tax rate | 42.3% | 43.5% | 43.4% | 43.9% | 43.8% | 43.4% | 41.5% | 39.1% |
| Net income | 46.8 | 45.8 | 42.2 | 36.4 | 26.4 | 21.9 | 15.6 | 14.0 |
| Net margin | 5.6% | 6.4% | 6.9% | 7.0% | 5.8% | 6.0% | 5.2% | 5.6% |
| |
| Diluted EPS | $1.68 | $1.65 | $1.51 | $1.29 | $0.94 | $0.78 | $1.12 | $1.01 |
| Shares outstanding (diluted) | 27.9 | 27.9 | 27.9 | 28.2 | 28.0 | 27.9 | 13.9 | 13.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|